The U.S. Centers for Medicare & Medicaid Services (CMS) announced the selection of 15 high-cost prescription drugs for the third cycle of the Medicare Drug Price Negotiation Program, marking the first ...
This article is the latest in the Health Affairs Forefront featured topic, “Health Policy at a Crossroads,” produced with the support of the Commonwealth Fund and the Robert Wood Johnson Foundation.
WASHINGTON, D.C. — Federal health officials announced that manufacturers of 15 high-cost prescription drugs have agreed to participate in the next round of Medicare drug price negotiations, a program ...
Recently approved delays and exemptions to the CMS drug price negotiation program are projected to cost $8.8 billion over 10 years, according to a Congressional Budget Office report published Oct. 20.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results